Amit Saxena,Ellen M. Ginzler,Keisha Gibson,Bancha Satirapoj,Adolfina Elizabeth Zuta Santillán,Olena Levchenko,Sandra Navarra,Tatsuya Atsumi,Shinsuke Yasuda,Nilmo Chávez-Pérez,Cristina Arriens,Samir V. Parikh,Dawn J. Caster,Vanessa Birardi,Simrat Randhawa,Laura Lisk,Robert B. Huizinga,Y.K. Onno Teng
AURORA 2 evaluated the long-term safety, tolerability, and efficacy of voclosporin compared to placebo in patients with lupus nephritis (LN) receiving an additional two years of treatment following completion of the one-year AURORA 1 study.